New bill would require childhood cancer drug studies alongside adult approvals

What does this do?

S 3302 requires drug companies seeking FDA approval for new adult cancer drugs to also study whether those drugs work against childhood cancers driven by the same genetic or molecular targets. These studies must produce usable data on safe dosing and early effectiveness signs for children of different ages. The bill also extends the Rare Pediatric Disease Priority Review Voucher program through September 2030.

Who does it affect?

The bill directly affects pharmaceutical and biotech companies developing cancer drugs and the FDA. Children with cancer or rare pediatric diseases, and their families, are the intended population.

Why does it matter?

Companies that might not otherwise pursue rare childhood disease treatments gain a financial incentive through vouchers that can be used or sold to speed FDA review of a separate drug. Government watchdog agencies must study and report to Congress on whether the rules result in more treatment options for children over time.

Where does it stand?